These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 19158127)
1. Equasy-- an overlooked addiction with implications for the current debate on drug harms. Nutt DJ J Psychopharmacol; 2009 Jan; 23(1):3-5. PubMed ID: 19158127 [No Abstract] [Full Text] [Related]
2. Using words: the harm reduction conception of drug use and drug users. Stafford N Int J Drug Policy; 2007 Mar; 18(2):88-91. PubMed ID: 17689350 [No Abstract] [Full Text] [Related]
3. How the harm reduction movement contrasts itself against punitive prohibition. Tammi T; Hurme T Int J Drug Policy; 2007 Mar; 18(2):84-7. PubMed ID: 17689349 [TBL] [Abstract][Full Text] [Related]
5. Drug policy, harm and human rights: a rationalist approach. Stevens A Int J Drug Policy; 2011 May; 22(3):233-8. PubMed ID: 21481578 [TBL] [Abstract][Full Text] [Related]
7. Examining the ethical boundaries of harm reduction: from addictions to general psychiatry. Lev-Ran S; Nitzan U; Fennig S Isr J Psychiatry Relat Sci; 2014; 51(3):175-80. PubMed ID: 25618280 [TBL] [Abstract][Full Text] [Related]
8. How Addiction handles disagreements over potentially harmful terminology. Humphreys K; Calder R; Marsden J; Day E Addiction; 2023 Oct; 118(10):1833-1834. PubMed ID: 37489005 [No Abstract] [Full Text] [Related]
9. [The issue of harm reduction in Polish legislation concerning drug addiction. A comparative study]. Sobeyko J Ann Acad Med Stetin; 2008; 54(2):119-31. PubMed ID: 19374242 [TBL] [Abstract][Full Text] [Related]
10. Nicotine and e-cigarettes: Rethinking addiction in the context of reduced harm. Cox S; Jakes S Int J Drug Policy; 2017 Jun; 44():84-85. PubMed ID: 28454011 [No Abstract] [Full Text] [Related]
11. Engaging the values-based ethical dilemmas in harm minimization: a response to Weatherburn. Fry CL; Irwin K Addiction; 2009 May; 104(5):862-3; author reply 863-4. PubMed ID: 19413798 [No Abstract] [Full Text] [Related]
12. Defending transparency at European drug regulator. Chirac P BMJ; 2020 Jan; 368():m10. PubMed ID: 31915125 [No Abstract] [Full Text] [Related]
13. Harm reduction is a good label for a criterion all drug programs should meet. Maccoun RJ Addiction; 2009 Mar; 104(3):341-2; discussion 345-6. PubMed ID: 19207338 [No Abstract] [Full Text] [Related]
14. Contingencies of the will: Uses of harm reduction and the disease model of addiction among health care practitioners. Szott K Health (London); 2015 Sep; 19(5):507-22. PubMed ID: 25394654 [TBL] [Abstract][Full Text] [Related]
15. PHARMAC welcomes debate. Moodie P; McNee W; Metcalfe S N Z Med J; 2005 Jul; 118(1218):U1572. PubMed ID: 16027757 [No Abstract] [Full Text] [Related]
16. Harm reduction is now the mainstream global drug policy. Wodak A Addiction; 2009 Mar; 104(3):343-5; discussion 345-6. PubMed ID: 19207340 [No Abstract] [Full Text] [Related]
20. Harm reduction coming of age: A summary of the '18th International Conference on the Reduction of Drug Related Harm'-Warsaw, Poland: 13-17 May 2007. Moskalewicz J; Barrett D; Bujalski M; Dabrowska K; Klingemann H; Klingemann J; Malczewski A; Struzik M Int J Drug Policy; 2007 Dec; 18(6):503-8. PubMed ID: 18061432 [No Abstract] [Full Text] [Related] [Next] [New Search]